LYSE LAURIN-PIERRE: Open Payments
NPI 1265751853 · WELLINGTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,476 in 14 payments from 11 companies in 2025. Trend: 2023 $712 · 2024 $770 · 2025 $1,476
Food & beverage: $1,476
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $260 |
| Novo Nordisk Inc | 2 | $174 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $145 |
| Alnylam Pharmaceuticals Inc. | 1 | $141 |
| SANOFI-AVENTIS U.S. LLC | 1 | $124 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Alexion Pharmaceuticals, Inc. | 1 | $122 |
| ABIOMED | 1 | $121 |
| Actelion Pharmaceuticals US, Inc. | 1 | $116 |
| Viatris Specialty LLC | 1 | $106 |
Products named: Wegovy, Biktarvy, AMVUTTRA, TZIELD, Symbravo, ULTOMIRIS, UPTRAVI, Epclusa.
Industry payments across FL — which companies pay providers there.
